NCT05316974Completed
Lymphoedema Among Persons With Head- and Neck Cancer
Lymphoedema for Persons With Head- and Neck Cancer
Source: ClinicalTrials.gov · Last updated 7 Oct 2025
Brief summary (registry, in English)
Lymphedema in the head and neck area is common after treatment for head and neck cancer. The aim of the research project is: • to assess the prevalence of lymphedema in patients with head and neck cancer (HNC) by measuring the amount of tissue water in the head and neck area before and after different kinds of cancer treatment, and to evaluate the quality of life before and after cancer treatment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 50 (actual)
- First submitted
- 21 Mar 2022
- Start date
- 1 Oct 2022
- Primary completion date
- 31 Oct 2024
- Lead sponsor
- Lund University
- Diseases
- Head and neck cancer
- NCT number
- NCT05316974
What you commit to
- Study type: Observational
- Participants enrolled: 50
- From 1 Oct 2022 to the primary completion date, 31 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment of HNC or radiation to the head and neck area.
- Planned surgery that includes free tissue transfer or pedicled flaps in the neck (local facial pedicled flaps are accepted).
- Planned proton therapy.
- Pre-treatment surgery or Botox injections in the tissue in the head and neck area.
Other
- Planned neck dissection involving less than three regions of the neck.
- Pregnancy
Who the study is looking for
- Biopsy or cytology confirmed HNC (all malignant types are accepted) from the oropharynx (OPC), oral cavity (OC) or neck metastases from unknown primary cancer of the head and neck (CUP).
- Tumour stage T1-4, N0-3.
- Planned for treatment with curative intent as recommended at the multidisciplinary tumour board.
- Age \>18 years. Able to give informed consent
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ENT department Skane University Hospital Coordinator of this site? Confirm its status | Lund | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.